AD4
Based on 1 publication(s) in Google Scholar
AD4 is a PROTAC that induces the degradation of PCLAF by recruiting cereblon. AD4 is also an artemisinin derivative. AD4 directly binds to PCLAF with a KD of 6.1 μM, and induces apoptosis and G1-phase cell cycle arrest. By degrading PCLAF, AD4 upregulates p21, reduces Rb phosphorylation, downregulates Bcl-2 and upregulates Bax, thereby activating the p21/Rb axis. AD4 can be used in studies related to acute B-lymphoblastic leukemia and PCLAF-dependent anticancer mechanisms .
(Pink: Caspase and Apoptosis ligand (HY-160962); Blue: Cereblon ligand (HY-14658); Black: linker (HY-W018678)).
For research use only. We do not sell to patients.
- Purity : 98.01%
- CAS No.: 2918262-09-4
- Formula: C55H78N4O15
- Molecular Weight:1035.23
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) AD4
MoreAll PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
PCLAF 54.92 nM (DC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RS4-11 | IC50 |
50.6 nM
|
Antiproliferative activity against human RS4;11 cancer cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 colorimetric assay.
Antiproliferative activity against human RS4;11 cancer cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 colorimetric assay.
|
37552639 |
| RPMI-8226 | IC50 |
235.3 nM
|
Antiproliferative activity against human RPMI8226 cancer cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 colorimetric assay.
Antiproliferative activity against human RPMI8226 cancer cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 colorimetric assay.
|
37552639 |
| U-266 | IC50 |
342.8 nM
|
Antiproliferative activity against human U266 cancer cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 colorimetric assay.
Antiproliferative activity against human U266 cancer cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 colorimetric assay.
|
37552639 |
In Vitro
AD4 (48 h) potently inhibits the proliferation of RS4;11 cells, RPMI8226 cells, and U266 cells, with IC50 values of 50.6 nM, 235.3 nM, and 342.8 nM, respectively[1].
AD4 (10-200 nM; 48 h) induces dose-dependent apoptosis in RS4;11 cells after 48 h of incubation, with the maximum effect observed at 200 nM[1].
AD4 (10-200 nM; 12-48 h) degrades PCLAF in RS4;11 cells in a dose-dependent manner, with a DC50 of 54.92 nM, while activating the p21/Rb pathway and regulating apoptosis-related proteins to exert antitumor activity [1].
AD4 (10-200 nM; 48 h) induces dose-dependent G1-phase cell cycle arrest in RS4;11 cells after 48 h of incubation, and exhibits superior activity to SM1044 (HY-160962) at matched concentrations [1].
AD4 directly binds to the purified PCLAF protein with a Kd value of 6.1 μM, and its affinity is higher than that of its parent compound SM1044[1].
PCLAF degradation induced by AD4 (0-48 h) in RS4;11 cells commences at 4 h and reaches its maximum level at 24 h[1].
AD4 (100 nM; washout)-induced degradation of PCLAF is reversible, and the PCLAF protein level fully recovers within 24 h after AD4 removal[1].
Co-treatment with AD4 (RS4;11; 12 h) and the parent compound SM1044 or the CRBN ligand pomalidomide restores PCLAF protein levels; the inactive PROTAC AD4a also fails to induce the same PCLAF degradation as AD4, which supports that the simultaneous binding of PCLAF and CRBN is an essential requirement for the degradation activity[1].
AD4 (100 μM; 45-75 °C for 10 min) increases the thermal stability of PCLAF in the CETSA assay[1].
AD4 (10-40 μM; room temperature for 0.5 h; Pronase E for 10 min) reduces the extent of proteolytic degradation of PCLAF in RS4;11 cell lysates[1].
AD4 exhibits a short metabolic half-life and rapid clearance in liver microsomes from humans and male Sprague-Dawley rats[1].
AD4 (100 nM; 12 h) significantly reduces the PCLAF protein level in RS4;11 cells; after combination with the proteasome inhibitor MG132 (HY-13259) (5 μM), the PCLAF protein level is restored, while other candidate proteins do not exhibit similarly prominent degradation[1].
AD4 (10-1000 nM) downregulates the anti-apoptotic protein Bcl-2 and upregulates the pro-apoptotic protein Bax in RS4;11 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RS4;11
-
Concentration:10 nM, 100 nM, 200 nM
-
Incubation Time:48 h
-
Result:Increased total apoptotic cells in a concentration-dependent manner.
Increased both early and late apoptotic populations.
Produced a slightly higher apoptotic fraction than SM1044 at 200 nM.
-
Cell Line:RS4;11
-
Concentration:10 nM, 100 nM, 200 nM
-
Incubation Time:48 h
-
Result:Induced G1-phase arrest in a concentration-dependent manner.
Produced greater G1-phase accumulation than SM1044 at the same concentration.
-
Cell Line:RS4;11
-
Concentration:AD4 100 nM; MG132 5 μM
-
Incubation Time:12 h
-
Result:Clearly reduced PCLAF protein among the candidate proteins examined.
Restored PCLAF protein upon combined exposure to MG132.
-
Cell Line:RS4;11
-
Concentration:100 nM
-
Incubation Time:Washout: 0-48 h
-
Result:Showed reversible PCLAF degradation.
Fully recovered PCLAF protein by 24 h after washout.
In Vivo
AD4 (1 or 5 mg/kg; i.v.; every other day) reduces the human ALL/RS4;11 cell burden in the spleen on day 10 of administration in female NOD/SCID mice engrafted with RS4;11, and prolongs the survival of mice in a dose-dependent manner, while no significant body weight loss or obvious adverse manifestations are observed[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID (female, 4-6 weeks old, acute B lymphoblastic leukemia xenograft with RS4;11 cells)[1]
-
Dosage:1 mg/kg; 5 mg/kg
-
Administration:i.v.; every other day
-
Result:Significantly inhibited growth of RS4;11 cells in mice.
Extended survival in a dose-dependent manner.
Caused no significant body weight loss or adverse effects.
-
Animal Model:NOD/SCID[1]
-
Dosage:25 mg/kg; 50 mg/kg; 100 mg/kg
-
Administration:i.v.; daily; 5 days
-
Result:Reached a maximum tolerated dose of 25 mg/kg.
Caused no significant body weight changes or organ lesions at 25 mg/kg.
Reduced survival at higher doses (50 mg/kg, 100 mg/kg).
Chemical Information
-
CAS No. 2918262-09-4
-
Appearance Solid
-
Molecular Weight 1035.23
-
Formula C55H78N4O15
-
Color Light yellow to yellow
-
SMILES
C[C@@H]1[C@@]2([H])[C@]34[C@@](O[C@@H]1OCCN(C(CCCCCCCNC5=C6C(C(N(C7C(NC(CC7)=O)=O)C6=O)=O)=CC=C5)=O)CCO[C@H]8O[C@@]9([H])[C@]%10%11[C@](CC[C@H]([C@]%10([H])CC[C@](O9)(OO%11)C)C)([H])[C@H]8C)([H])O[C@](OO3)(CC[C@@]4([H])[C@@H](CC2)C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Glia
Drosophila tweety facilitates autophagy to regulate mitochondrial homeostasis and bioenergetics in Glia. [Abstract]2024 Feb;72(2):433-451. PMID: 37870193
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (96.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
-
Data Sheet (292 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9660 mL | 4.8298 mL | 9.6597 mL | 24.1492 mL |
| 5 mM | 0.1932 mL | 0.9660 mL | 1.9319 mL | 4.8298 mL | |
| 10 mM | 0.0966 mL | 0.4830 mL | 0.9660 mL | 2.4149 mL | |
| 15 mM | 0.0644 mL | 0.3220 mL | 0.6440 mL | 1.6099 mL | |
| 20 mM | 0.0483 mL | 0.2415 mL | 0.4830 mL | 1.2075 mL | |
| 25 mM | 0.0386 mL | 0.1932 mL | 0.3864 mL | 0.9660 mL | |
| 30 mM | 0.0322 mL | 0.1610 mL | 0.3220 mL | 0.8050 mL | |
| 40 mM | 0.0241 mL | 0.1207 mL | 0.2415 mL | 0.6037 mL | |
| 50 mM | 0.0193 mL | 0.0966 mL | 0.1932 mL | 0.4830 mL | |
| 60 mM | 0.0161 mL | 0.0805 mL | 0.1610 mL | 0.4025 mL | |
| 80 mM | 0.0121 mL | 0.0604 mL | 0.1207 mL | 0.3019 mL |